Preview

Онкоурология

Расширенный поиск

ПОДДЕРЖИВАЮЩАЯ ВНУТРИПУЗЫРНАЯ ТЕРАПИЯ ВАКЦИНОЙ БЦЖ КАК СТАНДАРТ ПРОФИЛАКТИКИ И ЛЕЧЕНИЯ У БОЛЬНЫХ НЕМЫШЕЧНО-ИНВАЗИВНЫМ РАКОМ МОЧЕВОГО ПУЗЫРЯ ПРОМЕЖУТОЧНОЙ И ВЫСОКОЙ ГРУПП РИСКА

https://doi.org/10.17650/1726-9776-2012-8-3-12-17

Полный текст:

Аннотация

Несмотря на то, что терапия вакциной БЦЖ считается наиболее эффективным методом лечения и профилактики рецидивов немышечно-инвазивного рака мочевого пузыря, поддерживающий режим терапии применяется недостаточно часто. До сих пор остается нерешенным вопрос: требуется ли проведение пролонгированных курсов внутрипузырных инстилляций БЦЖ с целью получения оптимальных результатов?

Об авторах

Б. Я. Алексеев
МНИОИ им. П.А. Герцена
Россия


М. П. Головащенко
МНИОИ им. П.А. Герцена
Россия


Список литературы

1. Lamm D.L., Blumenstein B.A., Crissman J.D. et al. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol 2000;163:1124−9.

2. Sylvester R.J., van der Meijden A.P., Lamm D.L. Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a combined analysis of the published results of randomized clinical trials. J Urol 2002; 168:1964−70.

3. Böhle A., Jocham D., Bock P.R. Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal metaanalysis of comparative studies on recurrence and toxicity. J Urol 2003; 169:90−5.

4. Böhle A., Bock P.R. Intravesical bacilli Calmette-Guérin versus mitomycin C in superficial bladder cancer: formal metaanalysis of comparative studies on tumor progression. Urology 2004;63:682−6.

5. Sylvester R.J., van der Meijden A.P., Witjes J.A. et al. Bacillus Calmette-Guerin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: a meta-analysis of the published results of randomized clinical trials. J Urol 2005;174:86−91.

6. Han R.F., Pan J.G. Can intravesical bacillus Calmette-Guerin reduce recurrence in patients with superficial bladder cancer? A metaanalysis of randomized trials. Urology 2006;67:1216−23.

7. Malmström P.U., Sylvester R.J., Crawford D.E. et al. An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non-muscle-invasive bladder cancer. Eur Urol 2009;56:247−56.

8. Sylvester R.J., Brausi M.A., Kirkels W.J. et al. Long-term efficacy results of EORTC Genito-Urinary Group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Guerin, and bacillus Calmette-Guerin plus isoniazid in patients with intermediate- and high-risk stage Ta T1 urothelial carcinoma of the bladder. Eur Urol 2010;57:766−73.

9. Hinotsu S., Akaza H., Naito S. et al. Maintenance therapy with bacillus Calmette-Guerin (BCG) Connaught strain clearly prolongs recurrence-free survival following transurethral resection of bladder tumor (TURBT) for non-muscle-invasive transitional cell carcinoma of the bladder. BJU Int 2011;108(2):187−95.

10. Lamm D., Persad R., Colombel M., Brausi M. Maintenance Bacillus Calmette-Guerin: The standard of care for the prophylaxis and management of intermediateand high-risk non-muscle-invasive bladder cancer. Eur Urol Suppl 2010;9:715−34.

11. Taniguchi K., Koga S., Nishikido M. et al. Systemic immune response after intravesical instillation of bacille Calmette-Guerin (BCG) for superficial bladder cancer. Clin Exp Immunol 1999;115:131−5.

12. Chen F., Zhang G., Iwamoto Y., See W.A. BCG directly induces cell cycle arrest in human transitional carcinoma cell lines as a consequence of integrin cross-linking. BMC Urol 2005;5:8.

13. O’Donnell M.A., DeWolf W.C. BCG immunotherapy for superficial bladder cancer. New prospects for an old warhorse. Surg Oncol Clin North Amer 1995;4:189−202.

14. Prescott S., James K., Hargreave T.B. et al. Intravesical Evans strain BCG therapy: quantitative immunohistochemical analysis of the immune response within the bladder wall. J Urol 1992;147:1636−42.

15. Cookson M.S., Herr H.W., Zhang Z.F. et al. The treated natural history of high risk superficial bladder cancer: 15-year outcome. J Urol 1997;158:62−7.

16. Reichert D.F., Lamm D.L. Long term protection in bladder cancer following intralesional immunotherapy. J Urol 1984; 132:570−3.

17. Shelley M.D., Mason M.D., Kynaston H. Intravesical therapy for superficial bladder cancer: a systematic review of randomized trials and meta-analyses. Cancer Treat Rev 2010;36:195−205.

18. Bladder cancer: guideline for the management of non-muscle invasive bladder cancer (stages Ta,T1, and Tis): 2007 update. American Urological Association Web site. http://www.auanet.org/content/guidelinesand-quality-care/clinical-guidelines.cfm?sub=bc&CFID=673377&CFTOKEN=95927192&jsessionid=843082c98dcd9c03ed6c6863583e7735217f.

19. Babjuk M., Oosterlinck W., Sylvester R. et al. Guidelines on Ta, T1(non-muscle invasive) bladder cancer. European Association of Urology Web site. http://www.uroweb.org/gls/ pdf/TaT1%20(nonmuscle%20invasive)%20bladder%20cancer%202010.pdf.Updated 2009.

20. Lamm D., Colombel M., Persad R. et al. Clinical practice recommendations for the management of non-muscle invasive bladder cancer. Eur Urol Suppl 2008;7:651−66.

21. Soloway M.S., editor. International consultation on bladder tumours. Urology 2005;66 (Suppl 1):1−125.

22. Martinez-Pineiro J.A., Flores N., Isorna S. et al., for CUETO (Club Urologico Espanol de Tratamiento Oncologico). Long-term follow-up of a randomized prospective trial comparing a standard 81 mg dose of intravesical bacille Calmette-Guerin with a reduced dose of 27 mg in superficial bladder cancer. BJU Int 2002;89:671−80.

23. Martinez-Pineiro J.A., Martinez-Pineiro L., Solsona E. et al., for CUETO (Club Urologico Espanol de Tratamiento Oncologico). Has a 3-fold decreased dose of bacillus Calmette-Guerin the same efficacy against recurrences and progression of T1G3 and Tis bladder tumors than the standard dose? Results of a prospective randomized trial. J Urol 2005; 174:1242−7.

24. Lamm D., Böhle A., Palou J. et al. Re: Per-Uno Malmström, Richard J. Sylvester, David E. Crawford, et al. An individual patient data metaanalysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guerin for non-muscleinvasive bladder cancer. Eur Urol 2010; 57:p7−9.

25. Huncharek M., Kupelnick B. Impact of intravesical chemotherapy versus BCG immunotherapy on recurrence of superficial transitional cell carcinoma of the bladder: meta-analytic reevaluation. Am J Clin Oncol 2003;26:402−7.

26. Huncharek M., Kupelnick B. The influence of intravesical therapy on progression of superficial transitional cell carcinoma of the bladder: a meta-analytic comparison of chemotherapy versus bacilli Calmette-Guerin immunotherapy. Am J Clin Oncol 2004;27:522−8.

27. Järvinen R., Kaasinen E., Sankila A. et al. Long-term efficacy of maintenance bacillus Calmette-Guérin versus maintenance mitomycin C instillation therapy in frequently recurrent Ta, T1 tumours without carcinoma in situ: a subgroup analysis of the prospective, randomised FinnBladder I study with a 20-year follow-up. Eur Urol 2009; 56(2):260−5.

28. Witjes J.A., Palou J., Soloway M. et al. Clinical practice recommendations for the prevention and management of intravesical therapy associated adverse events. Eur Urol Suppl 2008;7:667−74.

29. Böhle A., Balck F., von Wietersheim J., Jocham D. The quality of life during intravesical bacillus Calmette-Guérin therapy. J Urol 1996;155:1221−6.

30. Lundholm C., Norlen B.J., Ekman P. et al. A randomized prospective study comparing long-term intravesical instillations of mitomycin C and bacillus Calmette-Guérin in patients with superficial bladder carcinoma. J Urol 1996;156:372−6.

31. Krege S., Giani G., Meyer R. et al. A randomized multicenter trial of adjuvant therapy in superficial bladder cancer: transurethral resection only versus transurethral resection plus mitomycin C versus transurethral resection plus bacillus Calmette-Guérin. Participating Clinics. J Urol 1996;156:962−6.

32. Lamm D.L. Complications of bacillus Calmette-Guérin immunotherapy. Urol Clin North Am 1992;19:565−72.

33. Falkensammer C., Gozzi C., Hager M. et al. Late occurrence of bilateral tuberculouslike epididymo-orchitis after intravescical bacille Calmette-Guerin therapy for superficial bladder carcinoma. Urology 2005;65:175.

34. Steg A., Leleu C., Debre B. et al. Systemic bacillus Calmette-Guérin infection: ‘BCGitis’ in patients treated by intravescical bacillus Calmette-Guérin therapy for bladder cancer. Eur Urol 1989;16:161−4.

35. Witjes J.A., Palou J., Soloway M. et al. Clinical practice recommendations for the prevention and management of intravesical therapy associated adverse events. Eur Urol Suppl 2008;7:667−74.

36. Rischmann P. Improving compliance of BCG immunotherapy: practical approaches to managing side-effects. Eur Urol Suppl 2006;5:660−2.

37. Picard A., Champetier D., Perrin P. et al. Discontinuance of BCG instillation for non-muscle invasive bladder cancer: prognostic impact on recurrence. Poster presented at: European Association of Urology 25th Annual Congress; April 16−20, 2010; Barcelona, Spain.

38. Van der Meijden A.P.M., Sylvester R.J., Oosterlinck W. et al. for the EORTC Genito-Urinary Tract Cancer Group. Maintenance bacillus Calmette-Guérin for Ta T1 bladder tumors is not associated with increased toxicity: results from a European Organisation for Research and Treatment of Cancer Genito-Urinary Group phase III trial. Eur Urol 2003;44:429−34.

39. Decobert M., LaRue H., Harel F. et al. Maintenance bacillus Calmette-Guérin in high-risk non-muscle invasive bladder cancer: how much is enough? Cancer 2008; 113:710−6.

40. Colombel M., Saint F., Chopin D. et al. The effect of ofloxacin on bacillus Calmette-Guérin induced toxicity in patients with superficial bladder cancer: results of a randomized, prospective, double-blind, placebo controlled, multicenter study. J Urol 2006; 176:935−9.

41. Buckley R., Rischmann P., Colombel M. et al. Prophylactic ofloxacin to improve tolerance of BCG instillations: two-year results of a prospective double-blind placebocontrolled study in patients with bladder cancer [Abstract PD-11.12]. Poster presented at: Societe Internationale d’Urologie (SIU) 28th Congress; November 12−16, 2006; Cape Town, South Africa.

42. Nieder A.M., Sved P.D., Stein J.P. et al. Cystoprostatectomy and orthotopic ileal neobladder reconstruction for management of bacille Calmette-Guérin-induced bladder contractures. Urology 2005;65:909−12.


Для цитирования:


Алексеев Б.Я., Головащенко М.П. ПОДДЕРЖИВАЮЩАЯ ВНУТРИПУЗЫРНАЯ ТЕРАПИЯ ВАКЦИНОЙ БЦЖ КАК СТАНДАРТ ПРОФИЛАКТИКИ И ЛЕЧЕНИЯ У БОЛЬНЫХ НЕМЫШЕЧНО-ИНВАЗИВНЫМ РАКОМ МОЧЕВОГО ПУЗЫРЯ ПРОМЕЖУТОЧНОЙ И ВЫСОКОЙ ГРУПП РИСКА. Онкоурология. 2012;8(3):12-17. https://doi.org/10.17650/1726-9776-2012-8-3-12-17

For citation:


Alekseev B.Y., Golovashchenko M.P. MAINTENANCE INTRAVESICULAR THERAPY WITH BCG VACCINE AS A STANDARD FOR THE PREVENTION AND TREATMENT OF NON-MUSCLE INVASIVE BLADDER CANCER IN MODERATE AND HIGH RISK GROUPS. Cancer Urology. 2012;8(3):12-17. (In Russ.) https://doi.org/10.17650/1726-9776-2012-8-3-12-17

Просмотров: 410


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1726-9776 (Print)
ISSN 1996-1812 (Online)
X